FDA's Breakthrough Designation is Working, Says Report

April 21, 2016
Jill Wechsler, Pharm Exec's Washington Correspondent

Jill Wechsler is Pharm Exec's Washington Corespondent

Pharmaceutical Executive

April 21, 2016.

The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .

Read Jill Wechsler's view in Applied Clinical Trials.